Drug intelligence / Profile preview

BEBT-809

Development stage: Unknown
Lead developer: BeBetter Med
Modality: Small Molecules
Administration: Oral

Overview

BEBT-809 is a first-in-class, oral small molecule inhibitor targeting the 20-HETE/GPR75 pathway. It acts as a G protein-coupled receptor 75 (GPR75) antagonist and has demonstrated favorable efficacy and safety compared to GLP-1 drugs in animal models. The drug is being developed primarily for the treatment of obesity and is currently in IND-regulated clinical trials. BEBT-809 was developed by BeBetter Med, Inc., also known as Guangzhou BeBetter Medicine Technology Co., LTD[1][2][3][4][8].

Targets

CYP4A11 (Cytochrome P450 family 4 subfamily A member 11)CYP4F2 (Cytochrome P450 family 4 subfamily F member 2)GPR75 (G protein-coupled receptor 75)

Beyond the preview

Go deeper on BEBT-809.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BEBT-809.